Rainmakers Awarded Centers for Disease Control and Prevention Contract to Study Multisystem Inflammatory Syndrome in Adults (MIS-A)
Ellicott City, MD – The Centers for Disease Control and Prevention (CDC) awarded Rainmakers Strategic Solutions LLC (Rainmakers) the Multisystem Inflammatory Syndrome in Adults (MIS-A) contract. The purpose of this initiative is to differentiate MIS-A from acute SARS-CoV-2 infection and estimate the prevalence of MIS-A among patients hospitalized with SARS-CoV-2 infection. By characterizing symptoms of these conditions, the CDC can provide effective treatment guidance to the public and providers.
“Rainmakers is excited about the opportunity to continue supporting the CDC in its COVID-19 research. Having worked with the CDC on the MIS-C Phenotype initiative, a similar project focusing on children, Rainmakers looks forward to continuing our partnership with the agency as it expands its Multisystem Inflammatory Syndrome initiatives.”
Rainmakers has an extensive background in program management and is already working with CDC on the Multisystem Inflammatory Syndrome study in children. This project expands our CDC COVID portfolio. Rainmakers will support the CDC by tracking the progress of administrative requirements, chart reviews, and 100 MIS-A cases and 200 SARS-CoV-2 control medical record case abstractions. We will also provide technical assistance to six participating hospitals across the country. Our technical approach to program management will ensure the study’s time-sensitivity will be addressed through strategic operational activities.
Share This